BridgeBio Pharma Total Change in Assets/Liabilities 2018-2024 | BBIO
BridgeBio Pharma annual/quarterly total change in assets/liabilities history and growth rate from 2018 to 2024. Total change in assets/liabilities can be defined as the sum of all line items in the Asset/Liability section of the Cash Flows Statement
- BridgeBio Pharma total change in assets/liabilities for the quarter ending December 31, 2024 was $0.032B, a 533.62% increase year-over-year.
- BridgeBio Pharma total change in assets/liabilities for the twelve months ending December 31, 2024 was $-0.153B, a 146.88% increase year-over-year.
- BridgeBio Pharma annual total change in assets/liabilities for 2024 was $0.032B, a 533.62% increase from 2023.
- BridgeBio Pharma annual total change in assets/liabilities for 2023 was $0.005B, a 81.99% decline from 2022.
- BridgeBio Pharma annual total change in assets/liabilities for 2022 was $0.028B, a 738.74% decline from 2021.
BridgeBio Pharma Annual Total Change in Assets/Liabilities
(Millions of US $) |
| 2024 |
$32 |
| 2023 |
$5 |
| 2022 |
$28 |
| 2021 |
$-4 |
| 2020 |
$15 |
| 2019 |
$-11 |
| 2018 |
$22 |
| 2017 |
$1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$6.894B |
$0.222B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
